Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03975231 · ClinicalTrials.gov registry record · Phase 1

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

A Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 1
Development phase
6
Enrollment target
3
Study locations

NCT03975231 is a Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 6 participants, below the 37-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03975231, a Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
3
Study locations

Study Summary

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.

Conditions Studied

Thyroid Gland Anaplastic Carcinoma BRAF NP_004324.2:p.V600E BRAF V600K Mutation Present

Interventions

  • RADIATION Intensity-Modulated Radiation Therapy
  • DRUG Trametinib
  • DRUG Dabrafenib

Study Locations (3)

California

  • City of Hope Medical Center - Duarte

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Texas

  • Univ of Texas-M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2020-09-14
Est. Completion 2026-02-28
Phase Phase 1

Sponsor

City of Hope Medical Center

582 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03975231

The ClinicalTrials.gov registry entry for NCT03975231 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target (84% lower). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Thyroid Gland Anaplastic Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Intensity-Modulated Radiation Therapy is the first listed.

NCT03975231 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT03975231 about?

NCT03975231 is a clinical study titled "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer". This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ra...

What is the current status of trial NCT03975231?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-14. Estimated completion is 2026-02-28.

What conditions does trial NCT03975231 study?

This clinical trial studies the following conditions: Thyroid Gland Anaplastic Carcinoma, BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present.

What interventions are being tested in trial NCT03975231?

The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION), Trametinib (DRUG), Dabrafenib (DRUG).

Who is sponsoring clinical trial NCT03975231?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03975231 being conducted?

This trial has 3 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Gland Anaplastic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Gland Anaplastic Carcinoma

All registered trials for this condition

BRAF NP_004324.2:p.V600E

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.